SJS Investment Consulting’s Definium Therapeutics DFTX Stock Holding History

SJS Investment Consulting’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.94K	Buy	51 +47	+1,175%	+$1.98K	﹤0.01%	2228
2026 Q2	$189	Buy	+4	New	+$99	﹤0.01%	2488
2024 Q4	–	Sell	-12	Closed	-$69	–	1667
2024 Q3	$69	Hold	12	–	–	﹤0.01%	1595
2024 Q2	$87	Hold	12	–	–	﹤0.01%	1587
2024 Q1	$113	Sell	12 -2	-14%	-$11	﹤0.01%	1561
2023 Q4	$52	Hold	14	–	–	﹤0.01%	1589
2023 Q3	$44	Hold	14	–	–	﹤0.01%	1598
2023 Q2	$50	Hold	14	–	–	﹤0.01%	1561
2023 Q1	$45	Hold	14	–	–	﹤0.01%	1527
2022 Q4	$31	Buy	14 +12	+600%	+$33	﹤0.01%	1564
2022 Q3	$0	Buy	+2	New	+$19	﹤0.01%	1342
2022 Q1	$0	Sell	2 -267	-99%	-$4.63K	﹤0.01%	1105
2021 Q4	$6K	Buy	+269	New	+$8.59K	﹤0.01%	410

Other funds holding DFTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

SJS Investment Consulting's DFTX Position: Q3 2026 in Review

SJS Investment Consulting increased its Definium Therapeutics (DFTX) stake by 1,175% in Q3 2026, buying an estimated $1.98K and bringing the position to 51 shares worth $1.94K. The position accounts for ﹤0.01% of the portfolio, ranked #2228.

SJS Investment Consulting first reported a position in DFTX in Q4 2021 and has held it in 13 quarters since. The position peaked at $6K in Q4 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

SJS Investment Consulting held 51 shares of Definium Therapeutics worth $1.94K as of Q3 2026.
SJS Investment Consulting bought 47 Definium Therapeutics shares in Q3 2026, an estimated $1.98K.
Definium Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2228 holding.
SJS Investment Consulting first reported a position in Definium Therapeutics in Q4 2021 and has held it in 13 quarters since.
SJS Investment Consulting's Definium Therapeutics position peaked at $6K in Q4 2021.
159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.